Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.

The aim of this study was to evaluate the effects of docosahexaenoic acid (DHA) on the intestinal cytochrome P450 isoenzyme (CYP3A) and P-glycoprotein (P-gp) functions using midazolam and rhodamine-123 as specific substrates of CYP3A and P-gp, respectively. Perfused everted intestinal segments from rats were employed to determine the effects of DHA on midazolam metabolism and rhodamine-123 transport. In addition, the effects of DHA on in vitro midazolam metabolism in rat intestinal microsomes and on midazolam bioavailability in rats were examined. The intestinal extraction ratio (ER G) of midazolam was determined to be 0.43 and decreased significantly to 0.12, 0.07, and 0.06 in the presence of 50, 100, and 200 microM DHA, respectively, in a concentration-dependent manner. The results from an in vitro study using rat intestinal microsomes demonstrated that DHA competitively inhibited the intestinal CYP3A activity with Ki of 15.7 and 27.1 microM for the formations of 1'-OH midazolam and 4-OH midazolam, respectively. Moreover, the oral administration of DHA (100mg/kg) increased the AUC infinity, Cmax, and oral bioavailability (F) of midazolam by about 50% in rats, without affecting the T 1/2, V dss/F, or CL tot/F. In contrast, DHA did not change the serosal-to-mucosal transport of rhodamine-123 in the perfused everted intestine and oral administration of DHA (100mg/kg) had no influence on the pharmacokinetics of intravenously administered midazolam in rats, thus suggesting that DHA has little effect on the intestinal P-gp activity and hepatic clearance of midazolam. This study provided the first direct evidence to show that DHA has an inhibitory effect on the intestinal pre-systemic metabolism of a CYP3A substrate and that DHA has little, if any, effect on the P-gp activity in the gut.

[1]  Hitoshi Sato,et al.  DEMONSTRATION OF DOCOSAHEXAENOIC ACID AS A BIOAVAILABILITY ENHANCER FOR CYP3A SUBSTRATES: IN VITRO AND IN VIVO EVIDENCE USING CYCLOSPORIN IN RATS , 2006, Drug Metabolism and Disposition.

[2]  G. Tucker,et al.  Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. , 2002, British journal of anaesthesia.

[3]  Y. Sugiyama,et al.  Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P 4503A4 , 1999, AAPS PharmSci.

[4]  Hitoshi Sato,et al.  Docosahexaenoic acid (DHA) inhibits saquinavir metabolism in‐vitro and enhances its bioavailability in rats , 2006, The Journal of pharmacy and pharmacology.

[5]  Peggy Gandia,et al.  The Perfused Everted Intestinal Segment of Rat , 2004, Arzneimittelforschung.

[6]  D. Greenblatt,et al.  In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat , 2002, Journal of Pharmacology and Experimental Therapeutics.

[7]  T. Henthorn,et al.  Carrier-mediated uptake of rhodamine 123: implications on its use for MDR research. , 2000, Biochemical and biophysical research communications.

[8]  J. Gorski,et al.  Interaction between midazolam and clarithromycin in the elderly. , 2008, British journal of clinical pharmacology.

[9]  M. Grever,et al.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. , 1994, Molecular pharmacology.

[10]  Mark M. Roden,et al.  Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein , 1999, Pharmaceutical Research.

[11]  M. Tomita,et al.  Regional difference in P-glycoprotein function in rat intestine. , 2005, Drug metabolism and pharmacokinetics.

[12]  C. Goho.  Oral midazolam-grapefruit juice drug interaction. , 2001, Pediatric dentistry.

[13]  J. Houston,et al.  The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.

[14]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[15]  D. Elliott,et al.  Grapefruit juice and potential drug interactions. , 2003, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[16]  D. Greenblatt,et al.  Molecular and Pharmacokinetic Evaluation of Rat Hepatic and Gastrointestinal Cytochrome P450 Induction by Tamoxifen , 2001, Pharmacology.

[17]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[18]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[19]  S. Teshima,et al.  Pharmacokinetics of Dietary 13C‐Labeled Docosahexaenoic Acid and Docosapentaenoic Acid in Red Sea Bream Chrysophrys major , 2002 .

[20]  Kwang-Hyeon Liu,et al.  INHIBITORY EFFECTS OF FRUIT JUICES ON CYP3A ACTIVITY , 2006, Drug Metabolism and Disposition.

[21]  T. Murakami,et al.  Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. , 1999, The Journal of pharmacology and experimental therapeutics.

[22]  D. Dunbar,et al.  Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[23]  J. Polli,et al.  Midazolam Exhibits Characteristics of a Highly Permeable P-Glycoprotein Substrate , 2003, Pharmaceutical Research.

[24]  C. Chen,et al.  The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. , 2006, Life sciences.

[25]  T. Murakami,et al.  Dose‐dependent Intestinal and Hepatic First‐pass Metabolism of Midazolam, a Cytochrome P450 3A Substrate with Differently Modulated Enzyme Activity in Rats , 1999, The Journal of pharmacy and pharmacology.

[26]  H. Lennernäs,et al.  Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine , 2003, The Journal of pharmacy and pharmacology.

[27]  P. Watkins,et al.  First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. , 1999, The Journal of pharmacology and experimental therapeutics.

[28]  Y Zhang,et al.  Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[29]  L. Arterburn,et al.  A developmental safety study in rats using DHA- and ARA-rich single-cell oils. , 2000, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[30]  D. Shen,et al.  First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.

[31]  M. Niemi,et al.  Functional interaction of intestinal CYP3A4 and P‐glycoprotein , 2004, Fundamental & clinical pharmacology.

[32]  H. Bays.  Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. , 2006, The American journal of cardiology.

[33]  J. A. Carrillo,et al.  Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. , 1998, Therapeutic drug monitoring.

[34]  Y. Sawada,et al.  Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. , 2002, Drug metabolism and pharmacokinetics.

[35]  L. Benet,et al.  Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. , 2004, International journal of pharmaceutics.

[36]  G Houin,et al.  Gastrointestinal absorption of drugs: methods and studies , 1999, Fundamental & Clinical Pharmacology.